Related references
Note: Only part of the references are listed.Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome
Vacis Tatarunas et al.
SCIENTIFIC REPORTS (2020)
Platelet reactivity patterns in patients treated with dual antiplatelet therapy
Max-Paul Winter et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2019)
Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis
Anna Komosal et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Switching between P2Y12 antagonists - From bench to bedside
Aleksandra Gasecka et al.
VASCULAR PHARMACOLOGY (2019)
Effectiveness of Antiplatelet Drugs Under Therapeutic Hypothermia: A Comprehensive Review
Ceren Eyileten et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Shedding Light on Long-Term Effects of Early Antiplatelet Strategies After Fibrinolytic Treatment in STEMI
Christian Hengstenberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
Max-Paul Winter et al.
SCIENTIFIC REPORTS (2019)
Relationship of Platelet Reactivity and Inflammatory Markers to Recurrent Adverse Events in Patients with ST-Elevation Myocardial Infarction
Krishma Adatia et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Genetic Variability of SRC Family Kinases and Its Association with Platelet Hyperreactivity and Clinical Outcomes: A Systematic Review
Lukasz Milanowski et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Ticagrelor - toward more efficient platelet inhibition and beyond
Michal J. Kubisa et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Clopidogrel in Critically Ill Patients
Christian Schoergenhofer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina
Piotr Niezgoda et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Prasugrel in critically ill patients
Christian Schoergenhofer et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction
Ruiwei Guo et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy
April Ann Cox et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors
Max-Paul Winter et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi et al.
EUROPEAN HEART JOURNAL (2016)
Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor
Jolanta M. Siller-Matula et al.
PLATELETS (2016)
From C-Reactive Protein to Interleukin-6 to Interleukin-1 Moving Upstream To Identify Novel Targets for Atheroprotection
Paul M. Ridker
CIRCULATION RESEARCH (2016)
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor
Jolanta M. Siller-Matula et al.
VASCULAR PHARMACOLOGY (2016)
Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
Dimitrios Alexopoulos et al.
CARDIOVASCULAR DIABETOLOGY (2015)
The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study
Claudia Schuette et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls
Max-Paul Winter et al.
POSTEPY W KARDIOLOGII INTERWENCYJNEJ (2015)
Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study
Marek Rosiak et al.
CARDIOLOGY JOURNAL (2013)
Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study
Jolanta M. Siller-Matula et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Response Variability to P2Y12 Receptor Inhibitors Expectations and Reality
Jolanta M. Siller-Matula et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2013)
Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding
Udaya S. Tantry et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Inflammation in Atherosclerosis
Peter Libby
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Recent Advances on the Role of Cytokines in Atherosclerosis
Hafid Ait-Oufella et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Christian W. Hamm et al.
EUROPEAN HEART JOURNAL (2011)
Update on lipids, inflammation and atherothrombosis
Lina Badimon et al.
THROMBOSIS AND HAEMOSTASIS (2011)
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Christian W. Hamm et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease
Karin Mueller et al.
ATHEROSCLEROSIS (2010)
Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel
Steen Husted et al.
CLINICAL CARDIOLOGY (2010)
Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay
J. M. Siller-Matula et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment
Isabell Bernlochner et al.
THROMBOSIS AND HAEMOSTASIS (2010)
The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients
A. M. Gori et al.
ATHEROSCLEROSIS (2009)
Platelets: Inflammatory firebugs of vascular walls
Andreas E. May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Chao-Yung Wang et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation
Tobias Geisler et al.
DIABETES CARE (2007)
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Platelet inhibition by insulin is absent in type 2 diabetes mellitus
IA Ferreira et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome
YG Chen et al.
CHINESE MEDICAL JOURNAL (2006)
Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention
MJ Quinn et al.
AMERICAN JOURNAL OF CARDIOLOGY (2004)
Implications of diabetes in patients with acute coronary syndromes - The Global Registry of Acute Coronary Events
K Franklin et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Beneficial cardiovascular pleiotropic effects of statins
J Davignon
CIRCULATION (2004)
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells
S Devaraj et al.
CIRCULATION (2003)
Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets
CD Garlichs et al.
HEART (2001)
Soluble CD40L and cardiovascular risk in women
U Schönbeck et al.
CIRCULATION (2001)
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
PM Ridker et al.
CIRCULATION (2000)
Share Paper
